Abstract
The galactomannan assay to diagnose invasive aspergillosis is recommended and clinically utilized, yet the mechanism of galactomannan release from Aspergillus fumigatus is unknown. We used an A. fumigatus strain lacking calcineurin A (cnaA), already shown to be critically important for pathogenicity, to evaluate galactomannan kinetics. During the logarithmic growth phase when glucose was consumed, β-D-galactofuranoside (galf)-antigens were released in the culture. However, after glucose became limited, GM release further increased in the supernatants of the wild type strain while there was no further increase of GM release in the ΔcnaA strain. β-Galactofuranosidase activity was also decreased in the ΔcnaA mutant, and the amount of galf-antigen in the cell wall fraction of the ΔcnaA mutant was approximately ten-fold higher. This suggests the possibility that the antigen is unable to be released due to a cell wall abnormality. This and previous work suggest a dynamic calcineurin-dependent cell wall during periods of growth, with galactomannan release from the cell wall possibly calcineurin-dependent and reflected in the decreased GM release and greatly increased cell wall fraction of galf in the ΔcnaA mutant.
Similar content being viewed by others
References
Mennink-Kersten MA, Ruegebrink D, Wasei N, Melchers WJ, Verweij PE (2006) In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1, 3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol 44:1711–1718
Latge JP, Kobayashi H, Debeaupuis JP, Diaquin M, Sarfati J, Wieruszeski JM, Parra E, Bouchara JP, Fournet B (1994) Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect Immun 62:5424–5433
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360
Sarfati J, Boucias DG, Latgé JP (1995) Antigens of Aspergillus fumigatus produced in vivo. J Med Vet Mycol 33:9–14
Steinbach WJ, Reedy JL, Cramer RA Jr, PJ R, Heitman J (2007) Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5:418–430
Steinbach WJ, Cramer RA Jr, Perfect BZ, Asfaw YG, Sauer TC, Najvar LK, Kirkpatrick WR, Patterson TF, Benjamin DK Jr, Heitman J, Perfect JR (2006) Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell 5:1091–1103
Steinbach WJ, Cramer RAJ, Perfect BZ, Henn C, Nielsen K, Heitman J, Perfect JR (2007) Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother 51:2979–2981
Acknowledgments
WJS was supported by a K08 A1061149 award, a Basic Science Faculty Development grant from the American Society for Transplantation, and a Children’s Miracle Network grant.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mennink-Kersten, M.A.S.H., Ruegebrink, D., Verweij, P.E. et al. Calcineurin-dependent galactomannan release in Aspergillus fumigatus . Eur J Clin Microbiol Infect Dis 30, 551–553 (2011). https://doi.org/10.1007/s10096-010-1118-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-010-1118-5